
Experimental Colorectal Cancer Drug Dostarlimab Leading to Remission
In a small clinical study, dostarlimab has led to 100% remission for colorectal cancer patients. Dr. Mohamedtaki Tejani explains how it works and which patients qualify for this treatment.